Evidence-based·Updated November 19, 2026·How we grade evidence

Survodutide

PeptideInvestigational weight-loss drug (not FDA-approved)

Survodutide is an investigational once-weekly injection that acts on the GLP-1 and glucagon receptors. In a 76-week phase 3 trial, adults with obesity lost on average 12.2% to 13.0% of their body weight, compared with 5.4% on placebo, and in a heart safety trial of 5530 adults it did not raise the risk of heart events. It also cut liver fat in people with fatty liver disease. It is not FDA-approved, and about 1 in 5 people stopped it because of stomach side effects in the heart safety trial.

Taking Survodutide with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with obesity, type 2 diabetes or fatty liver disease who qualify for and choose to join a registered clinical trial; everyone else can ask a doctor about approved options

Common dosing range

No approved dose. Phase 3 trials raised the dose to 3.6 mg or 6.0 mg injected once weekly

When to expect effects

Liver fat measured at 48 weeks; weight loss measured at 46 to 76 weeks

Watch out for

Not FDA-approved and cannot be prescribed outside a trial; FDA has warned sellers of unapproved "research" survodutide. Nausea and vomiting were very common, and about 1 in 5 people stopped because of stomach side effects in the heart safety trial

What is it

Survodutide is an investigational drug that is not FDA-approved for any use, so it cannot be prescribed outside a clinical trial, and any product sold now as survodutide (including vials labeled "for research use only") is unapproved and unverified. FDA has warned companies that illegally sold unapproved drugs containing survodutide falsely labeled "for research purposes" or "not for human consumption" for human use. Its developer, Boehringer Ingelheim, is testing it as a once-weekly injection in phase 3 trials for obesity (the SYNCHRONIZE program) and for the liver disease MASH (the LIVERAGE trials). Phase 3 results in obesity, obesity with type 2 diabetes, fatty liver disease and heart safety were published in 2026; the liver trials and several others are still running on ClinicalTrials.gov.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You meet the entry criteria of a registered survodutide trial (listed on ClinicalTrials.gov), for example in obesity or MASH, and decide with the study team that you want to take part
You would rather wait to see whether FDA approves it and, meanwhile, discuss approved weight-loss, diabetes or MASH medicines with a prescriber
You have fatty liver disease with obesity and want to follow the liver trial results with your doctor

Probably skip if…

You would be buying it online or from a "research peptide" seller: FDA has warned companies selling survodutide this way
You have a personal or family history of medullary thyroid cancer or MEN 2, you have had pancreatitis, or you have severe gastroparesis; people with these conditions were excluded from the trials
You are pregnant, trying to become pregnant or breastfeeding
You have trouble tolerating nausea and vomiting: these were the main reasons people stopped in trials

Evidence at a glance

weight loss in adults with obesity without diabetes

Good Evidence
Effect
-12.2% (3.6 mg) and -13.0% (6.0 mg) vs -5.4% on placebo at 76 weeks (SYNCHRONIZE-1)
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Time
Measured at 46 to 76 weeks

weight loss in adults with type 2 diabetes

Good Evidence
Effect
-8.2% (3.6 mg) and -9.8% (6.0 mg) vs -3.9% on placebo at 76 weeks
Best fit
Adults with type 2 diabetes and a BMI of 27 or more
Time
Measured at 76 weeks

liver fat in fatty liver disease (MASLD) with obesity

Good Evidence
Effect
84.2% vs 24.3% reached at least a 30% reduction in liver fat (efficacy estimand); 68.5% vs 28.6% (treatment regimen estimand)
Best fit
Adults with obesity and fatty liver disease with inflammation or scarring on tests
Time
Measured at 48 weeks

heart events (heart death, stroke, heart attack, artery-opening procedures or heart failure)

Good Evidence
Effect
Hazard ratio 0.89 (95% CI 0.67 to 1.18): no increase in heart events, no proven reduction
Best fit
Adults with obesity and established heart disease or high heart risk
Time
Median 22 months of follow-up

MASH (fatty liver inflammation) with liver scarring

Limited Evidence
Effect
MASH improvement in 43% to 62% vs 14% on placebo
Best fit
Adults with biopsy-confirmed MASH and fibrosis stage F1 to F3
Time
Measured at 48 weeks

Evidence for 5 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

weight loss in adults with obesity without diabetes

Disease adjunct
Good Evidence

In SYNCHRONIZE-1, a phase 3 trial of 725 adults with obesity, or overweight with a weight-related condition, and without diabetes, once-weekly survodutide for 76 weeks lowered body weight by an average of 12.2% (3.6 mg) and 13.0% (6.0 mg), compared with 5.4% on placebo; 72.6% and 71.9% lost at least 5%, compared with 46.3% on placebo. These averages include people who stopped treatment. In the 46-week phase 2 trial of 387 adults, weight fell by 6.2% to 14.9% depending on dose, compared with 2.8% on placebo, but only 61% of those on survodutide (and 60% on placebo) completed the 46 weeks of treatment. Both trials were funded by Boehringer Ingelheim.

Effect size
-12.2% (3.6 mg) and -13.0% (6.0 mg) vs -5.4% on placebo at 76 weeks (SYNCHRONIZE-1)
Time to effect
Measured at 46 to 76 weeks
Best fit
Adults with a BMI of 30 or more, or 27 or more with a weight-related condition, without diabetes
Less likely
People with type 2 diabetes, who lost less weight in SYNCHRONIZE-2; people who cannot tolerate nausea and vomiting

Bottom line: Meaningful weight loss over 76 weeks; no head-to-head trial against an approved drug has been published.

weight loss in adults with type 2 diabetes

Disease adjunct
Good Evidence

In SYNCHRONIZE-2, a 76-week phase 3 trial of 752 adults with type 2 diabetes and a BMI of 27 or more (average HbA1c 7.4%), body weight fell by 8.2% (3.6 mg) and 9.8% (6.0 mg), compared with 3.9% on placebo. HbA1c fell by 0.9 and 0.8 percentage points, compared with 0.2 on placebo. The trial was funded by Boehringer Ingelheim and did not test diabetes complications.

Effect size
-8.2% (3.6 mg) and -9.8% (6.0 mg) vs -3.9% on placebo at 76 weeks
Time to effect
Measured at 76 weeks
Best fit
Adults with type 2 diabetes and a BMI of 27 or more
Less likely
People with type 1 diabetes, who were not studied

Bottom line: People with type 2 diabetes lost less weight than people without diabetes in the companion trial.

liver fat in fatty liver disease (MASLD) with obesity

Biomarker support
Good Evidence

In SYNCHRONIZE-MASLD, a 48-week phase 3 trial in the United States and Spain, 216 adults with obesity and fatty liver disease with signs of inflammation or scarring received survodutide 6.0 mg weekly or placebo. Liver fat, measured by MRI, fell by at least 30% in 84.2% of people on survodutide, compared with 24.3% on placebo, among those who stayed on treatment (68.5% vs 28.6% counting everyone). The trial measured liver fat on scans, not liver failure, cirrhosis or survival, and its authors list the short duration as a limitation.

Effect size
84.2% vs 24.3% reached at least a 30% reduction in liver fat (efficacy estimand); 68.5% vs 28.6% (treatment regimen estimand)
Time to effect
Measured at 48 weeks
Best fit
Adults with obesity and fatty liver disease with inflammation or scarring on tests
Less likely
People with cirrhosis, who are being studied in a separate ongoing trial

Bottom line: It clearly lowers liver fat; whether that prevents serious liver disease is still being tested.

heart events (heart death, stroke, heart attack, artery-opening procedures or heart failure)

No benefit found
Good Evidence

SYNCHRONIZE-CVOT was a phase 3 heart safety trial of 5530 adults with obesity or overweight (BMI of 27 or more) and heart disease, kidney disease or several heart risk factors, followed for a median of 22 months. It measured a combined outcome of heart death, nonfatal stroke, nonfatal heart attack, procedures to open heart arteries and heart failure events. This occurred in 3.7% of people on survodutide and 4.1% on placebo (hazard ratio 0.89). The trial met its goal of showing that survodutide did not increase this risk, but the difference was too small to show a reduction: it was designed and analyzed as a safety trial, not to prove a heart benefit.

Effect size
Hazard ratio 0.89 (95% CI 0.67 to 1.18): no increase in heart events, no proven reduction
Time to effect
Median 22 months of follow-up
Best fit
Adults with obesity and established heart disease or high heart risk
Less likely
Anyone expecting heart protection: this trial did not show it

Bottom line: Reassuring on heart safety, but no evidence yet that it prevents heart attacks or strokes.

MASH (fatty liver inflammation) with liver scarring

Disease adjunct
Limited Evidence

In a 48-week phase 2 trial, 293 adults with biopsy-confirmed MASH and liver scarring (fibrosis stage F1 to F3) received survodutide 2.4, 4.8 or 6.0 mg weekly or placebo. Liver inflammation improved without worse scarring on repeat biopsy in 47%, 62% and 43%, compared with 14% on placebo. Scarring improved by at least one stage in 34% to 36%, compared with 22% on placebo. Phase 3 trials that measure liver outcomes (LIVERAGE) are still running.

Effect size
MASH improvement in 43% to 62% vs 14% on placebo
Time to effect
Measured at 48 weeks
Best fit
Adults with biopsy-confirmed MASH and fibrosis stage F1 to F3
Less likely
People with cirrhosis (stage F4), who were not in this trial

Bottom line: Promising biopsy results in one phase 2 trial; phase 3 confirmation is pending.

How it works

Survodutide activates two hormone receptors: GLP-1, the target of semaglutide, and the receptor for glucagon. GLP-1 signals reduce appetite, slow stomach emptying and help insulin release after meals. Glucagon is a hormone that normally raises blood sugar, but its receptor is targeted here for its effects on energy use and on fat processing in the liver, which is why survodutide is also being tested for fatty liver disease. It is injected under the skin once a week, and the dose is raised in steps. Unlike tirzepatide and retatrutide, it does not act on the GIP receptor.

How to take it

1. Typical dose
There is no approved dose. In the phase 3 trials, participants received survodutide injected under the skin once a week, with the dose raised in steps to 3.6 mg or 6.0 mg; dose flexibility was allowed. These are studied doses, not recommendations; in a trial the study team sets the dose.
2. Higher studied dose
6.0 mg once weekly is the highest phase 3 dose. The phase 2 obesity trial studied 0.6 to 4.8 mg weekly with a 20-week step-up, and the phase 2 MASH trial studied up to 6.0 mg.
3. Timing
Once a week by injection under the skin in trials
4. With food
Food instructions have not been established for this investigational drug
5. Split dosing
Not studied; trials used one weekly injection
6. How long to try
Phase 3 trials lasted 48 to 76 weeks, and the heart safety trial followed people for a median of 22 months. No results after stopping have been published

What to track

In a trial, the study visits and blood tests the study team schedules
Nausea, vomiting and diarrhea, and signs of dehydration such as dizziness or very little urine
Severe stomach pain that does not go away, with or without vomiting (a possible sign of pancreatitis in this drug class): get urgent care
Heart rate (it rose by an average of 3.6 beats a minute in one phase 3 trial)
Low blood sugar symptoms if you also take insulin or a sulfonylurea

Bottom line: Solid weight loss and liver fat results with reassuring heart safety data, but high rates of nausea and vomiting, and not approved: a trial is the only legitimate route.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Nausea (48.0% to 49.0% vs 12.1% on placebo in the heart safety trial)Vomiting (31.7% to 34.0% vs 4.8% on placebo in the heart safety trial)Stomach and gut symptoms overall, mostly mild to moderate (80.9% to 89.7% vs 47.9% on placebo in SYNCHRONIZE-1); in SYNCHRONIZE-MASLD they occurred mainly during the dose increaseFaster heart rate (an average rise of 3.6 beats a minute vs 0.8 on placebo at week 52 in SYNCHRONIZE-MASLD)

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: no data on survodutide in pregnancy are published. As a class warning, the labels of approved GLP-1 weight-loss drugs say they may cause fetal harm; the Wegovy label advises stopping semaglutide at least 2 months before a planned pregnancy. Breastfeeding: no data on survodutide in breast milk or in breastfed infants are published.

Interactions

Insulin and sulfonylureas (such as glipizide, glyburide or glimepiride)High

Class-based, not a finding for survodutide: the Wegovy (semaglutide) and Zepbound (tirzepatide) labels say that use with insulin or an insulin secretagogue such as a sulfonylurea may increase the risk of low blood sugar, including severe low blood sugar, and that reducing the dose of the insulin or secretagogue may be necessary. Survodutide has no FDA label.

Semaglutide, tirzepatide or other GLP-1 medicinesHigh

Class-based, not a finding for survodutide: survodutide acts on the GLP-1 receptor. The Wegovy label says use with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. SYNCHRONIZE-1 excluded people treated with obesity medicines in the 3 months before screening.

Oral medicines with a narrow safety margin (such as warfarin)Moderate

Class-based, not a finding for survodutide: the Zepbound label says tirzepatide delays stomach emptying and may affect the absorption of medicines taken by mouth, and says to monitor people taking oral medicines with a narrow therapeutic index (for example warfarin); the Wegovy label says to consider increased clinical or laboratory monitoring with such medicines. Published survodutide trials have not reported on this.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

The only legitimate source today is a registered clinical trial: the study is listed on ClinicalTrials.gov with an NCT number, and the study drug is supplied by the trial
In a trial you sign an informed consent form that names the sponsor, the study doctor and what is being tested
No pharmacy or telehealth service can supply FDA-approved survodutide, because no approved product exists

Be skeptical of…

"For research use only" or "not for human consumption" survodutide sold to the public with dosing instructions: FDA has warned companies selling it this way
"FDA-registered" or "has an NDC number, so it is approved": FDA says assignment of an NDC number does not denote FDA approval
"Protects your heart": the heart safety trial showed no increase in risk, not a reduction
"Cures fatty liver" or "reverses cirrhosis": phase 3 results so far show less liver fat on scans; liver outcome trials are still running
"Burns fat without side effects": nausea affected about half and vomiting about a third of people in the heart safety trial

Frequently asked questions

Is survodutide FDA-approved?⌄

No. As of November 19, 2026, it does not appear among FDA's approved drugs, and FDA calls products containing it unapproved drugs. It is in phase 3 trials run by Boehringer Ingelheim for obesity and for the liver disease MASH. Only FDA can decide whether it is approved.

Is it legal to buy survodutide online?⌄

Survodutide is an unapproved drug. FDA has warned companies that illegally sold it falsely labeled "for research purposes" or "not for human consumption", and it urges people not to buy these products, which are of unknown quality and may be harmful. A registered clinical trial is the only legitimate way to receive it now.

How does survodutide compare with semaglutide or tirzepatide?⌄

Survodutide acts on GLP-1 like semaglutide, plus the glucagon receptor instead of tirzepatide's GIP receptor. In its main phase 3 obesity trial, average weight loss at 76 weeks was 12.2% to 13.0%. No head-to-head trial against semaglutide or tirzepatide has been published, so numbers from different trials cannot be compared directly.

Is survodutide safe for the heart?⌄

In a phase 3 heart safety trial of 5530 adults followed for a median of 22 months, heart events were not more common than with placebo (3.7% vs 4.1%). The trial was not designed to show a heart benefit, and it did not show one. Survodutide did raise heart rate slightly in another trial.

Can I take survodutide with my supplements or other medicines?⌄

No interaction studies of survodutide with supplements have been published. Based on the labels of approved GLP-1 medicines, low blood sugar is a risk with insulin or sulfonylureas, the labels say using it with another GLP-1 medicine is not recommended, and slower stomach emptying may affect medicines taken by mouth. Ask a doctor or pharmacist to check your own list.

References by claim

weight loss in adults with obesity without diabetes

le Roux et al., 2026 · PubMed (2026) link

le Roux et al., 2024 · PubMed (2024) link

weight loss in adults with type 2 diabetes

Wharton et al., 2026 · PubMed (2026) link

liver fat in fatty liver disease (MASLD) with obesity

Kaplan et al., 2026 · PMC (2026) link

MASH (fatty liver inflammation) with liver scarring

Sanyal et al., 2024 · PubMed (2024) link

heart events (heart death, stroke, heart attack, artery-opening procedures or heart failure)

Bozkurt et al., 2026 · PubMed (2026) link

Safety

Wegovy (semaglutide) injection and tablets prescribing information · DailyMed (FDA label) link

ClinicalTrials.gov record NCT06066515 (SYNCHRONIZE-1): eligibility criteria · ClinicalTrials.gov link

FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss · FDA link

Interaction: Insulin and sulfonylureas (such as glipizide, glyburide or glimepiride)

Zepbound (tirzepatide) prescribing information · DailyMed (FDA label) link

Track Survodutide with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.